Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tilpisertib for adults with moderately to severely active ulcerative colitis has been terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Tilpisertib (Tilpisertib)

Snippet

Sponsor: Gilead Sciences | Conditions: Ulcerative Colitis | Phase 2 | Status: TERMINATED | Results posted: 2022-08-24